Abstract: Azenosertib (ZN-c3) is a highly potent, selective, and orally bioavailable WEE1 kinase inhibitor developed for the treatment of advanced and metastatic solid tumors. By targeting the G2/M cell cycle checkpoint, Azenosertib forces cancer cells—particularly those with p53 mutations—into premature mitosis, resulting in mitotic catastrophe and cell death. Compared to first-generation WEE1 inhibitors like adavosertib, Azenosertib demonstrates improved specificity and a significantly more favorable safety profile, particularly regarding hematological toxicities. Current clinical trials are evaluating its efficacy both as a monotherapy and in combination with other targeted agents, such as PARP and PD-1 inhibitors, across various solid tumors including ovarian and uterine carcinomas.
1. Introduction
The WEE1 kinase is a critical cell cycle regulatory protein that controls the timing of mitotic entry. It governs the G2/M checkpoint by phosphorylating and inhibiting Cyclin-dependent Kinase 1 (CDK1) and Cyclin-dependent Kinase 2 (CDK2), thereby preventing cells from entering mitosis when DNA damage is present [2]. In many human cancers, particularly those harboring mutations in the p53 tumor suppressor gene, the G1/S checkpoint is defective. Consequently, these cancer cells become highly dependent on the WEE1-mediated G2/M checkpoint to repair DNA damage and maintain genomic stability [1]. This dependency makes WEE1 an attractive therapeutic target. Azenosertib (also known as ZN-c3), developed by Zentalis Pharmaceuticals, is a novel, next-generation oral WEE1 inhibitor designed to overcome the limitations of earlier WEE1 inhibitors, such as adavosertib, by offering improved specificity and reduced toxicity for patients with advanced solid tumors [1][2].
2. Pharmacological Activity
Azenosertib has demonstrated impressive anti-tumor efficacy in preclinical and clinical studies involving solid tumors [2]. In a Phase 1 dose-escalation trial involving 55 patients with advanced or metastatic solid tumors, Azenosertib showed promising clinical activity, including partial responses in five patients and stable disease in others. One patient with a partial response exhibited a 42% reduction in overall tumor burden, while another showed a 56% reduction [1]. Based on the maximum tolerated dose (MTD) established in this trial, the recommended Phase II dose for Azenosertib is 300 mg administered orally once daily (QD) [1].
The compound is currently being evaluated in multiple clinical trials for various indications. These include NCT04158336 for advanced or metastatic solid tumors (as a single agent and in combination with the PARP inhibitor talazoparib or the PD-1 inhibitor pembrolizumab), NCT04516447 for platinum-resistant ovarian cancer, and NCT04814108 for recurrent or persistent uterine serous carcinoma [1][2]. Additional trials, such as NCT04972422, are also underway to further establish its clinical utility [2].
3. Molecular Mechanism of Action
Azenosertib functions by potently inhibiting the WEE1 kinase. Under normal physiological conditions, WEE1 phosphorylates CDK1 and CDK2, inhibiting the CDK1/Cyclin B complex and arresting the cell cycle at the G2/M phase to allow for DNA repair [1][2]. By inhibiting WEE1, Azenosertib prevents this inhibitory phosphorylation, effectively overriding the G2/M checkpoint. In cancer cells that already possess a defective G1/S checkpoint (such as those with p53 mutations), the abrogation of the G2/M checkpoint forces the cells to prematurely enter mitosis with unrepaired DNA damage. This accumulation of DNA damage and replication stress leads to aberrant chromosomal segregation, mitotic catastrophe, and ultimately, apoptotic cell death [1][2].
4. Structure-Activity Relationship (SAR)
While detailed structural modifications are not exhaustively described in the provided literature, Azenosertib (ZN-c3) is characterized as a highly potent and selective small-molecule inhibitor of WEE1. It exhibits an IC50 of 3.9 nM for WEE1 kinase inhibition [2]. The structural design of Azenosertib confers a significant advantage in specificity over first-generation inhibitors like adavosertib, which suffered from off-target effects (such as PLK1 inhibition) that contributed to high toxicity [1]. This improved selectivity profile is directly responsible for Azenosertib's enhanced tolerability and suitability for combination regimens [1][2].
5. Current Limitations
Despite its improved safety profile compared to earlier WEE1 inhibitors, Azenosertib is still associated with some treatment-emergent adverse effects. In the Phase 1 trial of 55 patients, side effects were predominantly mild to moderate. Gastrointestinal issues were the most common, with nausea affecting approximately half of the evaluable patients, while diarrhea and vomiting afflicted less than one-third. Fatigue was also reported in less than a third of the patients [1]. Notably, blood-related side effects, which severely limited the clinical utility of previous WEE1 inhibitors, were significantly reduced but still present: less than 10% of patients experienced hematological toxicities, specifically low white blood cell count (1.8%), low platelet count (7.2%), and anemia (7.2%) [1]. Managing these gastrointestinal and hematological toxicities remains a consideration for ongoing clinical application.
6. Future Perspectives
The future development of Azenosertib is heavily focused on combination therapies and biomarker-driven patient selection. Because of its favorable safety profile, Azenosertib is particularly well-suited for combination regimens. Ongoing trials are investigating its synergy with immunotherapies (e.g., the PD-1 inhibitor pembrolizumab) and DNA damage response inhibitors (e.g., the PARP inhibitor talazoparib) to overcome intrinsic resistance and enhance anti-tumor immunity [1]. Furthermore, identifying reliable predictive biomarkers is a critical unmet need. Clinical studies are currently correlating therapeutic response with circulating TP53 mutations (tested via TAm-Seq) and evaluating changes in pharmacodynamic markers such as pCDC2 and pH2AX in tumor and skin tissues [1]. Integrating Azenosertib into precision medicine frameworks based on these molecular signatures holds the potential to transform the treatment landscape for advanced solid tumors [2].
